Welcome to our dedicated page for Alumis news (Ticker: ALMS), a resource for investors and traders seeking the latest updates and insights on Alumis stock.
Alumis Inc. (Nasdaq: ALMS) is a late-stage biopharma and clinical-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases. The Alumis news feed on Stock Titan aggregates company press releases and market-moving updates so readers can review the latest disclosures directly from the issuer.
In its news releases, Alumis highlights progress across a pipeline centered on precision immunology. Key updates include clinical data and trial milestones for envudeucitinib (envu, formerly ESK-001), a next-generation, highly selective oral TYK2 inhibitor being studied in the Phase 3 ONWARD program for moderate-to-severe plaque psoriasis and the Phase 2b LUMUS trial in systemic lupus erythematosus. The company has reported positive topline Phase 3 results in plaque psoriasis and completion of enrollment in the LUMUS SLE study, along with prior Phase 2 data publications.
News items also cover advancement of A‑005, a potentially first‑in‑class fully CNS‑penetrant oral TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases, and lonigutamab, a subcutaneous anti‑IGF‑1R therapy for thyroid eye disease that has received Fast Track Designation from the U.S. Food and Drug Administration, as described by Alumis. Corporate and financial announcements include quarterly financial results, guidance on cash runway, collaboration revenue from Kaken Pharmaceutical, participation in healthcare investor conferences, and details of the company’s merger with ACELYRIN, Inc.
Investors following ALMS news can use this page to review updates on public offerings of common stock conducted under Alumis’ shelf registration statement, regulatory and clinical milestones for its late-stage programs, and other operational developments described in its press releases. Bookmark this news feed to monitor how Alumis communicates clinical progress, capital markets activity and strategic initiatives related to its immune-mediated disease pipeline.
Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Martin Babler, the company's President and CEO, will deliver a presentation at the virtual event on Tuesday, February 11, 2025, at 3:20 pm ET. Interested parties can access a live webcast of the presentation through the 'Events' page in the 'Investors' section of the Alumis website.
Alumis (ALMS) and ACELYRIN (SLRN) announced a merger agreement creating a late-stage clinical biopharma company focused on immune-mediated diseases. The all-stock transaction will result in Alumis stockholders owning ~55% and ACELYRIN stockholders ~45% of the combined company.
The merged entity will operate under the Alumis name with a pro forma cash position of approximately $737 million as of December 31, 2024, providing runway into 2027. The combined pipeline includes Alumis' ESK-001, currently in Phase 3 trials for psoriasis with topline data expected in H1 2026, and ACELYRIN's lonigutamab for thyroid eye disease.
The transaction is expected to close in Q2 2025, subject to stockholder approval. Stockholders representing ~62% of Alumis and ~24% of ACELYRIN have already agreed to support the merger.
Alumis (Nasdaq: ALMS) has strengthened its leadership team with key appointments to support its transition to a late-stage company. Jack Danilkowicz has been appointed as Chief Commercial Officer, bringing extensive experience in commercial strategies from Amgen and Horizon Therapeutics, where he helped grow annual net product sales from $300 million to nearly $4 billion.
Sara Klein has been promoted to Chief Legal Officer, continuing to direct corporate legal and compliance matters. Roy Hardiman, the previous legal officer, will now serve as Chief Business and Strategy Officer. These appointments come as Alumis advances its next-generation TYK2 inhibitor ESK-001 through Phase 3 ONWARD clinical program in plaque psoriasis and a potential pivotal Phase 2b trial in systemic lupus erythematosus.
Alumis (NASDAQ: ALMS) announced positive Phase 1 clinical trial results for A-005, their CNS penetrant TYK2 inhibitor. The trial demonstrated that A-005 successfully crosses the blood-brain barrier and achieves maximal TYK2 inhibition with favorable pharmacokinetics in both CNS and peripheral systems.
Key findings include: no serious adverse events reported, significant and prolonged exposure in cerebral spinal fluid, dose-proportional drug exposure, peak drug concentration with half-lives up to 12 hours, and established PK/PD relationship showing sustained TYK2 inhibition. The company plans to advance to Phase 2 clinical trials for multiple sclerosis in the second half of 2025.
Alumis (Nasdaq: ALMS) announced two data presentations at ACR Convergence 2024 highlighting their oral treatment ESK-001 for Systemic Lupus Erythematosus (SLE). The presentations demonstrate that ESK-001, a selective allosteric oral tyrosine kinase 2 (TYK2) inhibitor, effectively suppresses both a novel disease biomarker and Type 1 interferons, which are key drivers of SLE. The company's proprietary data analytics platform identified novel pathways in SLE that can be suppressed through TYK2 inhibition. The Phase 2b LUMUS study in SLE is ongoing, with top-line data expected in 2026.
Alumis (NASDAQ: ALMS) reported Q3 2024 financial results and recent achievements. The company presented promising data at EADV for ESK-001 in psoriasis treatment, with 93% of patients achieving PASI 75 at the 40mg twice daily dose. Currently advancing three clinical programs: Phase 3 ONWARD trials for psoriasis, Phase 2b for systemic lupus erythematosus, and Phase 1 for A-005 in neuroinflammatory diseases. Q3 financial results showed cash position of $361.9 million, expected to fund operations into 2026. Net loss increased to $93.1 million compared to $43.4 million in Q3 2023, with R&D expenses at $87.8 million and G&A expenses at $10.6 million.
Alumis (Nasdaq: ALMS) has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. President and CEO Martin Babler will engage in a fireside chat on Tuesday, November 12, 2024, at 2:00 pm ET in Boston, MA. The clinical-stage biopharmaceutical company, which focuses on developing oral therapies for immune-mediated diseases using precision approaches, will provide a live webcast of the event on their website's Investors section. The webcast recording will remain accessible for 90 days after the event.
Alumis Inc. (Nasdaq: ALMS) announced positive 28-week data from the open-label extension (OLE) of its Phase 2 STRIDE trial for ESK-001, an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis. The data, presented at the 2024 EADV Congress, showed:
- Dose-dependent sustained increases in PASI responses over time
- 93% of patients on 40 mg twice daily achieved PASI 75
- Favorable safety profile with mostly mild-to-moderate TEAEs
- Biomarker data supporting the 40 mg twice daily dose for Phase 3
The company expects to report full 52-week OLE data in 1H 2025 and is advancing ESK-001 in the Phase 3 ONWARD program. Additional presentations at EADV supported ESK-001's potential as a best-in-class treatment, showing improvements in quality of life and pruritus.
Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company, has announced its participation in several investor conferences in September 2024. The company, which focuses on developing oral therapies for immune-mediated diseases, will be present at five major healthcare and investment events:
1. Morgan Stanley Global Healthcare Conference (Sept. 5)
2. Wells Fargo Healthcare Conference (Sept. 6)
3. Baird Global Healthcare Conference (Sept. 11)
4. Cantor Fitzgerald Global Healthcare Conference (Sept. 17)
5. Stifel Immunology and Inflammation Virtual Summit (Sept. 18)
Alumis management will engage in various formats including fireside chats, presentations, and one-on-one investor meetings. Webcasts will be available for some events on the company's website.
Alumis Inc. (Nasdaq: ALMS) reported its Q2 2024 financial results and recent achievements. Key highlights include:
1. Initiated ESK-001 Phase 3 ONWARD clinical program for moderate-to-severe plaque psoriasis.
2. Started Phase 1 clinical trial for A-005 in healthy participants.
3. Completed IPO and private placement, raising $250M in gross proceeds.
4. Cash position of $209.5M as of June 30, 2024, expected to fund operations into 2026.
5. Q2 2024 financials: R&D expenses $48.6M, G&A expenses $7.6M, net loss $56.5M.
6. Upcoming milestones include ESK-001 Phase 2 OLE data update in psoriasis (Q3 2024) and A-005 Phase 1 clinical trial data (end of 2024).